News
TLX
11.84
+2.69%
0.31
Telix Pharma Aligns With FDA To Advance ProstACT Phase 3 Trial Of TLX591-Tx In Prostate Cancer
NASDAQ · 4h ago
BUZZ-Australia's Telix rises to over 9-month high as FDA backs ProstACT study advancement
Reuters · 8h ago
BRIEF-Telix Pharmaceuticals Says FDA Alignment To Advance ProstACT Global Phase 3 Trial
Reuters · 8h ago
FDA ALIGNMENT TO ADVANCE PROSTACT GLOBAL PHASE 3 TRIAL
Reuters · 8h ago
TELIX PHARMACEUTICALS - INITIATION OF PART 2 IN U.S. SUBJECT TO FDA IND AMENDMENT REVIEW
Reuters · 10h ago
William Blair updates conviction list: Oracle in, Meta out and more
Seeking Alpha · 22h ago
Weekly Report: what happened at TLX last week (0622-0626)?
Weekly Report · 2d ago
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
Barchart · 06/22 16:40
Weekly Report: what happened at TLX last week (0615-0619)?
Weekly Report · 06/22 10:37
Gubra appoints Lena Moran-Adams group general counsel
PUBT · 06/16 05:31
Weekly Report: what happened at TLX last week (0608-0612)?
Weekly Report · 06/15 10:37
Weekly Report: what happened at TLX last week (0601-0605)?
Weekly Report · 06/08 10:32
Telix Pharmaceuticals Signs MoU With United Imaging Healthcare North America To Evaluate A U.S. Research Collaboration On Advancing Integrated Theranostics Solutions
Benzinga · 06/02 11:17
Telix signs MOU with United Imaging to evaluate U.S. theranostics collaboration
PUBT · 06/02 11:02
TELIX AND UNITED IMAGING ANNOUNCE STRATEGIC THERANOSTICS COLLABORATION
Reuters · 06/02 11:00
William Blair updates its Conviction List
Seeking Alpha · 06/02 09:19
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
Barchart · 06/01 16:00
Weekly Report: what happened at TLX last week (0525-0529)?
Weekly Report · 06/01 10:38
Telix publishes investor presentation outlining radiopharmaceutical growth strategy and pipeline updates
PUBT · 06/01 05:48
Weekly Report: what happened at TLX last week (0518-0522)?
Weekly Report · 05/25 10:42
More
Webull provides a variety of real-time TLX stock news. You can receive the latest news about Telix Pharmaceuticals Ltd ADR through multiple platforms. This information may help you make smarter investment decisions.
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.